Retatrutide for Weight Loss in San Diego

Q: What are the side effects of retatrutide?

Phase 2 trial data showed that the most commonly reported side effects were gastrointestinal, including nausea, diarrhea, vomiting, and mild constipation. These effects were most common during the early dose titration phase and generally decreased over time as the body adjusted. A small temporary increase in resting heart rate was also observed at higher doses in some participants, which resolved over time. The overall side effect profile is consistent with other GLP-1 class medications.

Q: How is retatrutide administered and dosed?

Based on published Phase 2 and Phase 3 trial protocols, retatrutide is administered as a once weekly subcutaneous injection. Treatment begins at a low starting dose that is gradually increased over several weeks, a process designed to minimize side effects while the body adjusts. Final dosing guidelines will be established upon FDA approval and will be personalized by your physician based on your individual response and health profile.

Q: Is retatrutide safe for people with heart conditions?

Phase 2 data showed cardiovascular risk markers improved with retatrutide treatment, consistent with findings across the GLP-1 class. However, patients with existing heart conditions will require individual clinical evaluation to determine whether retatrutide is appropriate. Final cardiovascular safety data will be confirmed through the ongoing Phase 3 TRIUMPH cardiovascular outcomes trial.

Q: What happens if I switch from semaglutide or tirzepatide to retatrutide?

Transitioning from an existing GLP-1 medication to retatrutide will be evaluated on an individual basis once it becomes commercially available. Patients who have already made progress on semaglutide or tirzepatide may be strong candidates for retatrutide given their existing familiarity with GLP-1 treatment and established tolerability. Your provider will assess your current treatment response, health profile, and weight loss goals to determine whether a transition to retatrutide makes clinical sense for you.

Retatrutide for Weight Loss in San Diego

At Allurant Medical Spa, staying at the forefront of medical weight loss means paying attention to where obesity medicine is headed. Retatrutide stands as one of the most promising next generation weight loss medications currently in development. It builds on the clinical advancements that semaglutide and tirzepatide established. Retatrutide continues completing Phase 3 clinical trials and has not yet received FDA approval. Our team closely follows its progress and prepares to incorporate it into our physician supervised medical weight loss program once it becomes available. Early clinical research has demonstrated meaningful weight reduction and measurable metabolic improvement. Physicians and researchers now consider retatrutide one of the most anticipated emerging therapies in obesity medicine today.

What is Retatrutide?

Retatrutide is a new type of weight loss medication currently finishing its final round of clinical trials. Eli Lilly created it, the same company that made tirzepatide. It belongs to the same family of medications as semaglutide and tirzepatide. However, it works in a more advanced way than any weight loss medication currently available.

Retatrutide activates three hormone pathways at the same time: GLP-1, GIP, and glucagon. Each pathway plays a different role in how the body controls hunger, breaks down food, burns fat, and uses energy. By activating all three together, retatrutide produces a stronger and wider effect on the body than any single or dual pathway medication available today.

Early trial data has shown some of the highest weight loss results ever seen in a weight loss medication study. Researchers believe retatrutide could represent a major step forward in how doctors treat obesity. Eli Lilly has not yet received FDA approval for retatrutide and does not yet offer it for commercial use.

Why Do Patients Choose Retatrutide?

Record weight loss outcomes

Phase 2 data showed average weight loss of up to 24% of total body weight, higher than both semaglutide and tirzepatide in comparable timeframes.

A different mechanism entirely

Retatrutide does not just help you eat less. By activating the glucagon pathway, it may also help your body burn more calories on its own, even while at rest.

Broader metabolic benefits

Early data shows that patients using retatrutide experienced improvements in blood sugar levels, how the body responds to insulin, and reductions in liver fat, all alongside significant weight loss.

Built on a proven foundation

Retatrutide builds on the same foundation as semaglutide and tirzepatide, two of the most researched and proven weight loss medications available today.

What makes retatrutide different from all other GLP-1 medications?

All GLP-1 medications work by targeting hormone receptor pathways. These are signals in the body that control how you manage hunger, digestion, blood sugar, and fat storage. Most medications in this class target one or two of these pathways. Retatrutide targets three at the same time. No other approved GLP-1 medication currently does that.

The first pathway, GLP-1, helps reduce appetite and slows down digestion. The second pathway, GIP, makes that appetite reducing effect even stronger. GIP also helps the body respond better to insulin. The third pathway, glucagon, is what makes retatrutide truly different. Glucagon tells the body to break down stored fat for energy. It may also help the body burn more calories on its own, even while at rest. This means retatrutide does not just help you eat less. It may also help your body use energy more efficiently throughout the day.

That third pathway is what sets retatrutide apart from every other GLP-1 medication available today. It is not just a stronger version of what already exists. It takes a completely different approach to how the body loses weight at a biological level. Early research has produced results that scientists and doctors describe as unlike anything they have seen before in obesity treatment.

How does Retatrutide compare to other GLP-1 medications?

Each generation of GLP-1 medication has expanded the number of receptor pathways targeted and the average weight loss outcomes achieved. Here is how retatrutide compares to the two medications currently available at Allurant Medical Spa.

Retatrutide

Semaglutide

Retatrutide

Receptor pathway: Triple receptor GLP-1, GIP, and glucagon simultaneously
Average weight loss: Up to 24% of total body weight over 48 weeks in Phase 2 trials
Metabolic impact: May increase resting metabolic rate through glucagon receptor activation in addition to appetite regulation
Metabolic impact: May increase resting metabolic rate through glucagon receptor activation in addition to appetite regulation
Best suited for: Patients seeking the most advanced GLP-1 option once it becomes available

Tirzepatide

Who may be a candidate for retatrutide?

Retatrutide has not yet received FDA approval, but researchers are actively studying it in clinical trials. They are testing it in adults with obesity or excess weight. The patients they are studying share similar characteristics to those who qualify for existing GLP-1 weight loss medications.

Based on the patient groups researchers studied in Phase 2 and the ongoing Phase 3 trials, retatrutide may be a good fit for adults who:

Have a BMI of 30 or higher
Have a BMI of 27 or higher with at least one weight related health condition such as elevated blood pressure, insulin resistance, prediabetes, type 2 diabetes, high cholesterol, or metabolic dysfunction
Have struggled to achieve sustainable weight loss through diet and exercise alone
Are looking for a physician supervised medical weight loss approach with ongoing monitoring and individualized treatment adjustments
May not have achieved their desired results with semaglutide or tirzepatide

Retatrutide works on multiple pathways in the body at the same time. Because of this, researchers are looking into how it may help patients with more serious cases of obesity. They are also studying how it could benefit patients dealing with significant metabolic health issues.

Retatrutide is not yet available to the public. Eli Lilly and health regulators have not yet finalized the prescribing guidelines. Once the FDA approves retatrutide, our team at Allurant Medical Spa will sit down with you for a full medical evaluation. That conversation will help us determine whether retatrutide is the right choice for your health profile and weight loss goals.

Retatrutide clinical trial results and weight loss research

Retatrutide has finished Phase 2 clinical trials and the results have caught the attention of the medical community. Doctors and researchers in obesity medicine and medical weight loss have taken close note of the findings. In the Phase 2 study, patients who received the highest dose lost an average of approximately 24% of their total body weight. This happened over 48 weeks of treatment. These numbers represent some of the highest average weight loss results ever recorded in a medication based obesity study.

Retatrutide achieves these results by activating three hormone pathways at once: GLP-1, GIP, and glucagon. Each pathway influences how the body manages hunger and how much food a person takes in. Each pathway also influences how the body processes sugar, breaks down fat, and uses energy throughout the day.

Beyond weight reduction, clinical trial data has also shown meaningful improvements in several metabolic health markers commonly associated with obesity, including:

Blood sugar regulation

Insulin sensitivity

Liver fat reduction

Waist circumference

Cardiovascular risk markers

Body fat percentage

Eli Lilly is currently running Phase 3 clinical trials for retatrutide. This is the final stage of testing before regulators can review a medication for FDA approval. These larger studies examine long term safety and how well the medication works. They also examine whether dosing stays consistent and how retatrutide affects overall health outcomes. These trials include a wider and more varied group of patients than Phase 2 did.

Retatrutide has not yet received FDA approval and Eli Lilly does not yet offer it to the public. However, early data has made it one of the most talked about new treatments in obesity medicine. Doctors and researchers who have followed its development see it as an important step forward in physician supervised medical weight loss.

Frequently Asked Questions About Retatrutide in San Diego

What are the side effects of retatrutide?

Phase 2 trial data showed that patients most commonly reported gastrointestinal side effects, including nausea, diarrhea, vomiting, and mild constipation. These effects appeared most often during the early dose titration phase and generally decreased over time as the body adjusted. Some participants experienced a small temporary increase in resting heart rate at higher doses, which resolved over time. The overall side effect profile aligns with other GLP-1 class medications.

How is retatrutide administered and dosed?

Based on published Phase 2 and Phase 3 trial protocols, physicians administer retatrutide as a once weekly subcutaneous injection. Treatment begins at a low starting dose that gradually increases over several weeks, a process designed to minimize side effects while the body adjusts. Once the FDA approves retatrutide, your physician will establish and personalize your final dosing guidelines based on your individual response and health profile.

Will retatrutide cause muscle loss?

Any significant weight loss, whether from medication, diet, or surgery, can affect lean muscle mass alongside fat loss. Researchers are actively studying this in the ongoing Phase 3 TRIUMPH trials, and the research community awaits definitive retatrutide specific data on muscle preservation. What we know from the broader GLP-1 class is that combining treatment with resistance exercise and adequate protein intake meaningfully supports lean muscle retention during weight loss. Once retatrutide becomes available, our providers at Allurant Medical Spa will incorporate the same lifestyle guidance into your program.

Is retatrutide being studied for conditions other than weight loss?

Yes. Eli Lilly is currently studying retatrutide across multiple Phase 3 trials for conditions beyond obesity, including type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, chronic low back pain, cardiovascular and kidney outcomes, and metabolic dysfunction associated liver disease. This broad range of indications reflects the wide reaching metabolic effects the triple receptor mechanism produces.

Is retatrutide safe for people with heart conditions?

Phase 2 data showed retatrutide improved cardiovascular risk markers, consistent with findings across the GLP-1 class. However, patients with existing heart conditions will require individual clinical evaluation to determine whether retatrutide is appropriate. The ongoing Phase 3 TRIUMPH cardiovascular outcomes trial will confirm final cardiovascular safety data.

What happens if I switch from semaglutide or tirzepatide to retatrutide?

Your provider will evaluate a transition from an existing GLP-1 medication to retatrutide on an individual basis once it becomes commercially available. Patients who have already made progress on semaglutide or tirzepatide may be strong candidates for retatrutide given their existing familiarity with GLP-1 treatment and established tolerability. Your provider will assess your current treatment response, health profile, and weight loss goals to determine whether a transition to retatrutide makes clinical sense for you.

When will retatrutide be approved by the FDA?

Eli Lilly filed a New Drug Application with the FDA in late 2025. Based on current regulatory timelines, FDA approval is anticipated in late 2026 to 2027, though no confirmed approval date has been announced. Allurant Medical Spa will update this page and make retatrutide available to qualifying patients as soon as commercial availability begins.

Retatrutide Is on Its Way | Start Your GLP-1 Weight Loss Journey in San Diego Today

Retatrutide is on its way. When it arrives, Allurant Medical Spa will be ready to offer it to qualifying patients in San Diego. In the meantime, semaglutide and tirzepatide are available now. Both are part of our physician supervised medical weight loss programs. During your consultation, our medical team will review your health history. We will discuss your weight loss goals together. Our providers will determine which GLP-1 program is the right fit for you today. We will also map out a clear path forward as retatrutide becomes available.